Equity Overview
Price & Market Data
Price: $2.54
Daily Change: +$0.10 / 3.94%
Range: $2.44 - $2.54
Market Cap: $749,197,312
Volume: 4,555,285
Performance Metrics
1 Week: 17.29%
1 Month: 24.88%
3 Months: 14.09%
6 Months: -13.45%
1 Year: -33.07%
YTD: -14.33%
Company Details
Employees: 596
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.